GLP-1 and PPARγ Drugs Show Direct Brain Insulin-Signaling Effects
Stanford researchers find pioglitazone and liraglutide improve CNS insulin signaling, measured via neuron-derived vesicles in blood.
20 articles
Stanford researchers find pioglitazone and liraglutide improve CNS insulin signaling, measured via neuron-derived vesicles in blood.
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
GLP-1 receptor agonists show early promise for co-occurring substance use and mood disorders by targeting shared brain reward pathways.
A new oral GLP-1 receptor agonist penetrates the brain, restoring astrocyte-neuron metabolic crosstalk disrupted in Alzheimer's disease.
A Rutgers study finds GLP-1 users show dramatically weaker links between impulsivity, alcohol use, and violent behavior.
New NIH research reveals the brain-cell signaling mechanism behind GLP-1 drug plateaus and a potential way to extend their effects.
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
New research reveals GLP-1 drugs like Ozempic significantly reduce depression, anxiety, and substance use disorders alongside weight management.
Study shows 2'-fucosyllactose improves cognitive function in mice by modulating gut microbiota and brain serotonin levels.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A new study warns that diabetes medications could confound Alzheimer's biomarker studies, distorting our understanding of the diabetes-dementia link.
A Phase 1 trial examines how gadobutrol moves through and exits the bodies of newborns and toddlers undergoing routine contrast MRI.
New research reveals how melatonin prevents harmful protein aggregation linked to both type 2 diabetes and brain degeneration.
Breakthrough antisense therapy demonstrates sustained benefits for rare genetic form of ALS in extended clinical trial.
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.
New research reveals how glucose availability directs brain cell proliferation via a metabolic-epigenetic axis, with implications for MS and brain repair.
New research reveals how TSC2 mutations suppress translation of autism and epilepsy genes, offering potential therapeutic targets.
A boy with PLCB1-related epileptic encephalopathy showed improved seizure control and stabilized brain atrophy after high-dose enteral myo-inositol supplementation.
Dr. Gabrielle Lyon explains how GLP-1 medications affect muscle mass and shares strategies for maintaining muscle health during weight loss.
New research reveals how TDP-43 protein causes energy failure in motor neurons, pointing to potential metabolic therapies for ALS.